Li Yu
Impact in
- Oncology top 5%
- Lung Cancer Research Studies
-
- Lung Cancer Treatments and Mutations
- Brain Metastases and Treatment
Papers in
-
- Cancer therapeutics and mechanisms 4
- Glycosylation and Glycoproteins Research 2
-
- Lung Cancer Treatments and Mutations 10
- Co-authors
- Peter N. Morcos (7 shared papers)Kiharu Igarashi (1 shared paper)Yanqing Zang (1 shared paper)Sai‐Hong Ignatius Ou (1 shared paper)Leena Gandhi (1 shared paper)Frédéric Boisserie (1 shared paper)Howard West (1 shared paper)Shirish M. Gadgeel (1 shared paper)
- Journals
- Xenobiotica (3 papers)Journal of Pharmacology and Experimental Therapeutics (2 papers)Phytomedicine (2 papers)Investigational New Drugs (2 papers)Frontiers in Cardiovascular Medicine (2 papers)
- Partner nations
- ChinaUnited StatesSwitzerland
In The Last Decade
Li Yu
73 papers receiving 1.9k citations
Li Yu's Hit Papers
Peers
Comparison fields: 5 of 123
- Oncology 566
- Pulmonary and Respiratory Medicine 668
- Pharmacology 118
- Genetics 110
- Biochemistry 51
Countries citing papers authored by Li Yu
This map shows the geographic impact of Li Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li Yu more than expected).
Fields of papers citing papers by Li Yu
This network shows the impact of papers produced by Li Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li Yu. The network helps show where Li Yu may publish in the future.
Co-authors
The 25 scholars most cited alongside Li Yu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 75 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study Hit paper breakdown → | 2014 | 558 |
| 2 | 2007 | 160 | |
| 3 | 2016 | 139 | |
| 4 | 2007 | 80 | |
| 5 | 2020 | 66 | |
| 6 | 2005 | 56 | |
| 7 | 2016 | 56 | |
| 8 | 2004 | 51 | |
| 9 | 2013 | 49 | |
| 10 | 2018 | 41 | |
| 11 | 2016 | 38 | |
| 12 | 2008 | 36 | |
| 13 | 1997 | 34 | |
| 14 | 2010 | 29 | |
| 15 | 2021 | 28 | |
| 16 | 2017 | 26 | |
| 17 | 2016 | 25 | |
| 18 | 2023 | 25 | |
| 19 | 2016 | 24 | |
| 20 | 2018 | 23 |
About Li Yu
Li Yu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Oncology, Surgery and Pathology and Forensic Medicine, having authored 75 papers that have together received 1.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (10 papers), Pancreatic and Hepatic Oncology Research (5 papers), Cancer therapeutics and mechanisms (4 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers), Pancreatitis Pathology and Treatment (3 papers), Glycosylation and Glycoproteins Research (2 papers), Pregnancy and preeclampsia studies (2 papers) and Reproductive System and Pregnancy (2 papers). The work is most often cited by research in Oncology (566 citations), Pulmonary and Respiratory Medicine (668 citations), Pharmacology (118 citations), Genetics (110 citations) and Biochemistry (51 citations). Li Yu has collaborated with scholars based in China, United States and Switzerland. Frequent co-authors include Peter N. Morcos, Kiharu Igarashi, Yanqing Zang, Sai‐Hong Ignatius Ou, Leena Gandhi, Frédéric Boisserie, Howard West, Shirish M. Gadgeel, Michele C. Azada and Alberto Chiappori. Their work appears in journals such as Xenobiotica, Journal of Pharmacology and Experimental Therapeutics, Phytomedicine, Investigational New Drugs and Frontiers in Cardiovascular Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.